Betahistine and Weight- Related and Metabolic Measures in schizophrenic Patients Treated with Olanzapin or Risperidone
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT20191223045870N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 56
Patient or Legal Guardian Informed Consent
Have Schizophrenia Based on DSM5
18-59years old
Treated With Olanzapine or Risperidone That It Dosen't Change During The Study
Weight Gain At Least 7% Of Total Body Weight In The First Year of Treatment With Anti Psychotics Or In a Resent Year
If The Patient Is Taking Medication For Hyperlipidemia or Hypertention or Tyroid Disorders The Dose of Medication Did not Changed During The Study
The Patients Do not Have Another Medical or Psychiatric Disease
Do not Use Substance (Except Nicotine)
Have Asthma
Have Peptic Ulcer
Have Pheochromocytoma
Liver and Kidney Disfunction
Treated with Other Weight Related Medications Like Sodium Valproarte or Weight loss or Appetite Suppressant Medications
Have Allergy to Betahistine
Pregnant or Lactating
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Weight Related Measures(weight,waist and Hip circumfrence,BMI). Timepoint: At The Begining of the Study Then Every Month. Method of measurement: Weight measure with scales, Waist and Hip circumference measure with Meter.;Fasting blood sugar. Timepoint: At the Begining of The Study And After 12 weeks. Method of measurement: Laboratory Glucose kit.;Lipid profile include cholesterol and tri glyceride. Timepoint: At the Begining of The Study And After 12 weeks. Method of measurement: Laboratory cholestrol and triglycerid kits.;Thyroid stimulating hormone. Timepoint: At the Begining of The Study And After 12 weeks. Method of measurement: Enzyme linked immunosorbent test.
- Secondary Outcome Measures
Name Time Method